IMO-2055

Generic Name
IMO-2055
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
847484-35-9
Unique Ingredient Identifier
8566421Q5R
Indication

Investigated for use/treatment in renal cell carcinoma, solid tumors, and lung cancer.

Associated Conditions
-
Associated Therapies
-

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-08-06
Last Posted Date
2018-06-12
Lead Sponsor
Idera Pharmaceuticals, Inc.
Target Recruit Count
92
Registration Number
NCT00729053
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Georgetown University, Lombardi Cancer Center, Washington, District of Columbia, United States

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2008-07-21
Last Posted Date
2013-10-22
Lead Sponsor
EMD Serono
Target Recruit Count
21
Registration Number
NCT00719199
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Georgetown University Lombardi Cancer Center, Washington, DC, District of Columbia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-03-12
Last Posted Date
2013-10-22
Lead Sponsor
EMD Serono
Target Recruit Count
36
Registration Number
NCT00633529
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mary Crowley Medical Research Center, Dallas, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Central Indiana Cancer Centers, Indianapolis, Indiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cancer Therapy and Research Center, San Antonio, Texas, United States

and more 6 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath